Mankind Pharma is planning an expansion programme at its Paonta Sahib plant in Himachal Pradesh. It plans to invest Rs. 1500 million to enhance its presence in the US in the next 18 months and to generate revenue of $150 15million from the international market by 2030.
Currently, its domestic revenues are around Rs. 34,000 million and plans to reach Rs. 50,000 million by 2016.
The company has identified overseas markets, and will focus on cosmetics segment and the cardiovascular and anti-diabetic drug categories.